论文部分内容阅读
目的 体外研究奈非那韦耐性细胞株对其它抗艾滋病药及抗癌药的反应及与细胞凋亡的关系。方法 通过将成人T细胞白血病细胞株Jurkat培养于含有奈非那韦浓度不断增加直至 14 μm的培养液中培养 50d以获得耐奈非那韦的亚系细胞株JurkatrN。药敏试验用四唑嗡染色法 (类似XTT法 )并用流式细胞仪检测抗凋亡蛋白Bcl -2在母本和耐性Jurkat细胞中的表达。结果 发现JurkatrN细胞对d4T及新近报道的抗艾滋病药K -3 7的交叉耐性与母本细胞相比提高到 5倍左右。对抗肿瘤药CDDP ,VCR ,DOX和VP -16的交叉耐性也提高到 2 5倍以上。并且耐性细胞中心Bcl -2蛋白的荧光密度增加。结论 在用HIV -1蛋白酶抑制物奈非那韦作用后 ,Jurkat细胞对其它抗艾滋病药及抗肿瘤药产生了交叉耐性并且抗凋亡蛋白Bcl-2的表达增加
Objective To study the response of nelfinavir resistant cell line to other anti-AIDS drugs and anti-cancer drugs in vitro and its relationship with apoptosis. Methods Jurkat cells of Jurkat cell line resistant to nelfinavir were obtained by culturing adult T cell leukemia cell line Jurkat in a medium containing nelfinavir at a concentration of up to 14 μm for 50 days. Susceptibility test Tetrazolium staining (similar to the XTT method) was used and the expression of the anti-apoptotic protein Bcl-2 in female and resistant Jurkat cells was detected by flow cytometry. As a result, it was found that JurkatrN cells had a 5-fold increase in cross-resistance to d4T and the newly reported anti-AIDS drug K-37 compared to that of maternal cells. Cross-resistance to antineoplastic agents CDDP, VCR, DOX and VP-16 also increased to more than 25 fold. And the fluorescence density of the Bcl-2 protein in the center of the resistant cell is increased. Conclusions Jurkat cells developed cross-resistance to other anti-AIDS and antineoplastic agents and increased expression of the anti-apoptotic protein Bcl-2 after treatment with nelfinavir, an HIV-1 protease inhibitor